Testing RC48-ADC plus toripalimab for first-time urothelial cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether RC48-ADC combined with toripalimab works better as the first treatment for urothelial cancer that cannot be removed by surgery or has spread. It may help shrink tumors and improve outcomes in people whose cancer has the right HER2 and other eligibility features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You expect to live at least 12 weeks (your care team feels this is likely).
- Your urothelial cancer is advanced (cannot be removed) or metastatic, confirmed by a tissue biopsy from the kidney area, ureter, bladder, or urethra.
- You have not had prior whole-body (systemic) treatment for advanced urothelial cancer—except certain cases where chemotherapy was finished more than 6 months ago and the cancer came back.
- Your scans show at least one measurable tumor spot that can be tracked.
- Your cancer must be HER2-positive based on a central lab blood/tissue test: IHC 1+, 2+, or 3+.
- Your general health is good enough for treatment (ECOG 0 or 1), and your heart, blood counts, liver, kidneys, and clotting tests are adequate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs—9MW2821 (an antibody-drug conjugate) and Toripalimab (an immunotherapy)—given before and after surgery for muscle-invasive or high-risk urothelial cancer that has not spread. The goal is to see if this combined treatment can improve outcomes.
This trial is testing a new combination of two drugs (9MW2821 and toripalimab) against standard chemotherapy for people with advanced bladder cancer that has not been treated before. The goal is to see if this new approach works better at shrinking tumors or slowing the cancer's growth.
This trial tests a combination of an investigational drug (9MW2821) with an immunotherapy (toripalimab) against 9MW2821 alone for people with advanced urothelial cancer who have not yet received any systemic treatment. The goal is to see if the combination works better than the single drug.
This trial tests two drugs (toripalimab and 9MW2821) given before surgery for patients with upper tract urothelial cancer that hasn't spread. The goal is to see if this combination can shrink the tumor and improve outcomes.
This trial tests a combination of a targeted drug (disitamab vedotin), an immunotherapy (toripalimab), and radiation before surgery for people with high-risk upper tract urothelial cancer (UTUC). The goal is to see if this approach improves outcomes before and after surgery.
This trial is testing a new combination of two drugs—9MW2821 (a targeted therapy) and toripalimab (an immunotherapy)—for people with advanced bladder cancer. It aims to see if using them together can help shrink tumors or slow the cancer's growth.
Hear when a new Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.